Published in Chem Biol Drug Des on March 27, 2008
Therapeutic Targeting of Myc. Genes Cancer (2010) 1.68
Leveraging structure determination with fragment screening for infectious disease drug targets: MECP synthase from Burkholderia pseudomallei. J Struct Funct Genomics (2011) 0.92
Fragment-based discovery of novel thymidylate synthase leads by NMR screening and group epitope mapping. Chem Biol Drug Des (2010) 0.80
Cholera toxin inhibitors studied with high-performance liquid affinity chromatography: a robust method to evaluate receptor-ligand interactions. Chem Biol Drug Des (2009) 0.78
Synthesis and biological evaluation of pyrazolopyrimidines as potential antibacterial agents. Bioorg Med Chem Lett (2015) 0.75
Design of a novel globular protein fold with atomic-level accuracy. Science (2003) 13.06
RNA-binding proteins: modular design for efficient function. Nat Rev Mol Cell Biol (2007) 5.33
Genomic-scale prioritization of drug targets: the TDR Targets database. Nat Rev Drug Discov (2008) 2.58
The structure and function of small nucleolar ribonucleoproteins. Nucleic Acids Res (2007) 2.50
Toxoplasma gondii calcium-dependent protein kinase 1 is a target for selective kinase inhibitors. Nat Struct Mol Biol (2010) 2.34
Strong correlation between SHAPE chemistry and the generalized NMR order parameter (S2) in RNA. J Am Chem Soc (2008) 2.26
Recognition of GU-rich polyadenylation regulatory elements by human CstF-64 protein. EMBO J (2003) 2.01
Discovery of Potent and Selective Inhibitors of Calcium-Dependent Protein Kinase 1 (CDPK1) from C. parvum and T. gondii. ACS Med Chem Lett (2010) 1.82
Rational modification of a candidate cancer drug for use against Chagas disease. J Med Chem (2009) 1.73
A specific inhibitor of PfCDPK4 blocks malaria transmission: chemical-genetic validation. J Infect Dis (2013) 1.71
Protein families and RNA recognition. FEBS J (2005) 1.65
The protein farnesyltransferase inhibitor Tipifarnib as a new lead for the development of drugs against Chagas disease. J Med Chem (2005) 1.60
Second generation tetrahydroquinoline-based protein farnesyltransferase inhibitors as antimalarials. J Med Chem (2007) 1.60
Development of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) inhibitors with potent anti-toxoplasma activity. J Med Chem (2012) 1.56
The Cbf5-Nop10 complex is a molecular bracket that organizes box H/ACA RNPs. Nat Struct Mol Biol (2005) 1.52
High-resolution structural and thermodynamic analysis of extreme stabilization of human procarboxypeptidase by computational protein design. J Mol Biol (2006) 1.49
Structure of stem-loop IV of Tetrahymena telomerase RNA. EMBO J (2006) 1.49
The highly cooperative folding of small naturally occurring proteins is likely the result of natural selection. Cell (2007) 1.46
Efficacy, pharmacokinetics, and metabolism of tetrahydroquinoline inhibitors of Plasmodium falciparum protein farnesyltransferase. Antimicrob Agents Chemother (2007) 1.43
Rational design of inhibitors of HIV-1 TAR RNA through the stabilisation of electrostatic "hot spots". J Mol Biol (2004) 1.37
Selective inhibitors of methionyl-tRNA synthetase have potent activity against Trypanosoma brucei Infection in Mice. Antimicrob Agents Chemother (2011) 1.37
Missense mutations in the regulatory domain of PKC gamma: a new mechanism for dominant nonepisodic cerebellar ataxia. Am J Hum Genet (2003) 1.36
Multiple determinants for selective inhibition of apicomplexan calcium-dependent protein kinase CDPK1. J Med Chem (2012) 1.35
Urea-based inhibitors of Trypanosoma brucei methionyl-tRNA synthetase: selectivity and in vivo characterization. J Med Chem (2012) 1.35
Recognition of the iso-ADP-ribose moiety in poly(ADP-ribose) by WWE domains suggests a general mechanism for poly(ADP-ribosyl)ation-dependent ubiquitination. Genes Dev (2012) 1.33
Simultaneous recognition of HIV-1 TAR RNA bulge and loop sequences by cyclic peptide mimics of Tat protein. Proc Natl Acad Sci U S A (2009) 1.33
Cooperative interaction of transcription termination factors with the RNA polymerase II C-terminal domain. Nat Struct Mol Biol (2010) 1.32
A conserved RNA structure within the HCV IRES eIF3-binding site. Nat Struct Biol (2002) 1.31
An all-atom, distance-dependent scoring function for the prediction of protein-DNA interactions from structure. Proteins (2007) 1.28
Identification of CD46 binding sites within the adenovirus serotype 35 fiber knob. J Virol (2007) 1.27
Structural genomics of infectious disease drug targets: the SSGCID. Acta Crystallogr Sect F Struct Biol Cryst Commun (2011) 1.27
A new hydrogen-bonding potential for the design of protein-RNA interactions predicts specific contacts and discriminates decoys. Nucleic Acids Res (2004) 1.27
A knowledge-based potential function predicts the specificity and relative binding energy of RNA-binding proteins. FEBS J (2007) 1.26
Buffer optimization of thermal melt assays of Plasmodium proteins for detection of small-molecule ligands. J Biomol Screen (2009) 1.25
NMR studies of dynamics in RNA and DNA by 13C relaxation. Biopolymers (2007) 1.24
A novel calcium-dependent protein kinase inhibitor as a lead compound for treating cryptosporidiosis. J Infect Dis (2013) 1.23
Characterization of Trypanosoma brucei dihydroorotate dehydrogenase as a possible drug target; structural, kinetic and RNAi studies. Mol Microbiol (2008) 1.22
Transmission of malaria to mosquitoes blocked by bumped kinase inhibitors. J Clin Invest (2012) 1.22
Glycogen synthase kinase 3 is a potential drug target for African trypanosomiasis therapy. Antimicrob Agents Chemother (2008) 1.21
Structure-guided peptidomimetic design leads to nanomolar beta-hairpin inhibitors of the Tat-TAR interaction of bovine immunodeficiency virus. Biochemistry (2007) 1.20
How binding of small molecule and peptide ligands to HIV-1 TAR alters the RNA motional landscape. Nucleic Acids Res (2009) 1.20
The C-terminal domains of vertebrate CstF-64 and its yeast orthologue Rna15 form a new structure critical for mRNA 3'-end processing. J Biol Chem (2006) 1.20
Distinct states of methionyl-tRNA synthetase indicate inhibitor binding by conformational selection. Structure (2012) 1.18
Real-time multidimensional NMR follows RNA folding with second resolution. Proc Natl Acad Sci U S A (2010) 1.18
Resistance to a protein farnesyltransferase inhibitor in Plasmodium falciparum. J Biol Chem (2005) 1.18
13C NMR relaxation studies of RNA base and ribose nuclei reveal a complex pattern of motions in the RNA binding site for human U1A protein. J Mol Biol (2005) 1.18
Hydration dependent dynamics in RNA. J Biomol NMR (2009) 1.17
A new alpha-helical extension promotes RNA binding by the dsRBD of Rnt1p RNAse III. EMBO J (2004) 1.12
Benzoylbenzimidazole-based selective inhibitors targeting Cryptosporidium parvum and Toxoplasma gondii calcium-dependent protein kinase-1. Bioorg Med Chem Lett (2012) 1.12
Structural mimicry of retroviral tat proteins by constrained beta-hairpin peptidomimetics: ligands with high affinity and selectivity for viral TAR RNA regulatory elements. J Am Chem Soc (2004) 1.11
Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery. J Med Chem (2010) 1.11
Structurally simple inhibitors of lanosterol 14alpha-demethylase are efficacious in a rodent model of acute Chagas disease. J Med Chem (2009) 1.10
TAR RNA recognition by a cyclic peptidomimetic of Tat protein. Biochemistry (2005) 1.09
Cloning and analysis of Trypanosoma cruzi lanosterol 14alpha-demethylase. Mol Biochem Parasitol (2003) 1.08
Pharmacological characterization, structural studies, and in vivo activities of anti-Chagas disease lead compounds derived from tipifarnib. Antimicrob Agents Chemother (2012) 1.08
Solution and crystallographic studies of branched multivalent ligands that inhibit the receptor-binding of cholera toxin. J Am Chem Soc (2002) 1.08
Structure and stability of wild-type and mutant RNA internal loops from the SL-1 domain of the HIV-1 packaging signal. J Mol Biol (2002) 1.07
Protein and RNA dynamics play key roles in determining the specific recognition of GU-rich polyadenylation regulatory elements by human Cstf-64 protein. J Mol Biol (2005) 1.07
How arginine-rich domains coordinate mRNA maturation events. RNA Biol (2007) 1.07
The solution structure of an essential stem-loop of human telomerase RNA. Nucleic Acids Res (2003) 1.06
Structural basis for stabilization of the tau pre-mRNA splicing regulatory element by novantrone (mitoxantrone). Chem Biol (2009) 1.06
The structure of an enzyme-activating fragment of human telomerase RNA. RNA (2005) 1.06
Engineering RNA-binding proteins for biology. FEBS J (2013) 1.06
γ-AApeptides bind to RNA by mimicking RNA-binding proteins. Org Biomol Chem (2011) 1.06
Validation of automated docking programs for docking and database screening against RNA drug targets. J Med Chem (2004) 1.05
Binding of U1A protein changes RNA dynamics as observed by 13C NMR relaxation studies. Biochemistry (2007) 1.05
Solid-state deuterium NMR studies reveal micros-ns motions in the HIV-1 transactivation response RNA recognition site. J Am Chem Soc (2008) 1.05
Biogenesis of peroxisomes and glycosomes: trypanosomatid glycosome assembly is a promising new drug target. FEMS Microbiol Rev (2004) 1.02
2-Oxotetrahydroquinoline-based antimalarials with high potency and metabolic stability. J Med Chem (2008) 1.01
Characterization and crystal structure of a high-affinity pentavalent receptor-binding inhibitor for cholera toxin and E. coli heat-labile enterotoxin. J Am Chem Soc (2002) 1.00
Essential structural requirements for specific recognition of HIV TAR RNA by peptide mimetics of Tat protein. Nucleic Acids Res (2010) 1.00
Using fragment cocktail crystallography to assist inhibitor design of Trypanosoma brucei nucleoside 2-deoxyribosyltransferase. J Med Chem (2006) 1.00
Novel protein-protein contacts facilitate mRNA 3'-processing signal recognition by Rna15 and Hrp1. J Mol Biol (2010) 1.00
The box H/ACA RNP assembly factor Naf1p contains a domain homologous to Gar1p mediating its interaction with Cbf5p. J Mol Biol (2007) 0.99
Resistance mutations at the lipid substrate binding site of Plasmodium falciparum protein farnesyltransferase. Mol Biochem Parasitol (2006) 0.99
Structures of substrate- and inhibitor-bound adenosine deaminase from a human malaria parasite show a dramatic conformational change and shed light on drug selectivity. J Mol Biol (2008) 0.98
Inhibition of both HIV-1 reverse transcription and gene expression by a cyclic peptide that binds the Tat-transactivating response element (TAR) RNA. PLoS Pathog (2011) 0.97
Crystal structures of trypanosomal histidyl-tRNA synthetase illuminate differences between eukaryotic and prokaryotic homologs. J Mol Biol (2010) 0.97
High-resolution structural validation of the computational redesign of human U1A protein. Structure (2006) 0.96
In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose. Pharmacogenet Genomics (2005) 0.95
Nonspanning bivalent ligands as improved surface receptor binding inhibitors of the cholera toxin B pentamer. Chem Biol (2004) 0.95
Design of beta-hairpin peptidomimetics that inhibit binding of alpha-helical HIV-1 Rev protein to the rev response element RNA. Angew Chem Int Ed Engl (2007) 0.95
Mitoxantrone analogues as ligands for a stem-loop structure of tau pre-mRNA. J Med Chem (2009) 0.94
Monitoring tat peptide binding to TAR RNA by solid-state 31P-19F REDOR NMR. Nucleic Acids Res (2005) 0.94
Cell-free production of functional Plasmodium falciparum dihydrofolate reductase-thymidylate synthase. Mol Biochem Parasitol (2006) 0.93
Structure of Leishmania major methionyl-tRNA synthetase in complex with intermediate products methionyladenylate and pyrophosphate. Biochimie (2010) 0.93